Structure-based repurposing of FDA-approved drugs as TNF-α inhibitors

Research output: Journal Publications and ReviewsRGC 21 - Publication in refereed journalpeer-review

44 Scopus Citations
View graph of relations

Author(s)

  • Chung-Hang Leung
  • Daniel Shiu-Hin Chan
  • Maria Hiu-Tung Kwan
  • Zhen Cheng
  • Guo-Yuan Zhu
  • Wang-Fun Fong
  • Dik-Lung Ma

Detail(s)

Original languageEnglish
Pages (from-to)765-768
Journal / PublicationChemMedChem
Volume6
Issue number5
Publication statusPublished - 2 May 2011

Abstract

Old dogs, new tricks! We applied structure-based virtual screening methods to identify small-molecule inhibitors of tumor necrosis factor-α (TNF-α) from a database of 3000 US Food and Drug Administration (FDA)-approved drugs. Darifenacin (Enablex) and ezetimibe (Zetia) were identified as direct TNF-α inhibition, representing only the fifth and sixth examples of small-molecule TNF-α inhibitors. © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Research Area(s)

  • Approved drugs, Drug discovery, Inhibitors, Tumor necrosis factor, Virtual screening

Citation Format(s)

Structure-based repurposing of FDA-approved drugs as TNF-α inhibitors. / Leung, Chung-Hang; Chan, Daniel Shiu-Hin; Kwan, Maria Hiu-Tung et al.
In: ChemMedChem, Vol. 6, No. 5, 02.05.2011, p. 765-768.

Research output: Journal Publications and ReviewsRGC 21 - Publication in refereed journalpeer-review